Please login to the form below

Not currently logged in


This page shows the latest NASH news and features for those working in and with pharma, biotech and healthcare.

Genfit claims FDA breakthrough status for liver disease drug

Genfit claims FDA breakthrough status for liver disease drug

Meanwhile, Cymabay has its own NASH PPAR candidate in its pipeline, which is due for a crucial data readout in mid-2019. ... The US based biopharma claims its drug can reduce fat associated with NASH by 30%, suggesting a strong competitive profile.

Latest news

More from news
Approximately 19 fully matching, plus 33 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    treatments for NASH with Pfizer products. Not. disclosed. One of the big deals for Novartis these last two months was the long‐rumoured sale of it’s Sandoz division’s US ... The agreement is driven by the belief that liver diseases will respond

  • Taking a lean and careful approach Taking a lean and careful approach

    A lot of NASH patients also have these conditions so we want to look at and understand the underlying causes to see what else we can come up with there.”. ... The NASH market is expected to be worth $20bm by 2025 and financial brokers recently valued

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    Oncology, immuno-oncology and central nervous system therapies once again topped the charts, but 2016 also saw the emergence of new areas, notably non-alcoholic steatohepatitis or NASH. ... With NASH appearing to be a long-term consequence of obesity it

  • Deal Watch December 2016 Deal Watch December 2016

    The Scandinavian company, Nuevolution, uses its drug discovery platform Chemetics to discover novel small molecules in the field of chronic inflammatory diseases, including psoriasis, rheumatoid arthritis, non-alcoholic steato-hepatitis (NASH),

  • Deal Watch September 2016 Deal Watch September 2016

    Taking advantage of the drop in Tobira's market cap following disappointing results from the phase IIb studies in NASH, Allergan still paid a significant amount to secure the business with ... This acquisition brings a phase I oral DPP 4, evogliptin, and

More from intelligence
Approximately 1 fully matching, plus 8 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 2 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company

Fendix is the only NHS digital media network and it provides organisations, such as pharma, with unrivalled digital access to...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...